» Articles » PMID: 28653990

The Between Now and Then of Lung Cancer Chemotherapy and Immunotherapy

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Jun 28
PMID 28653990
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer.

Citing Articles

Characterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.

Li H, Qin Z, Huang X, Wei Z, Deng J Heliyon. 2025; 11(4):e42720.

PMID: 40066042 PMC: 11891687. DOI: 10.1016/j.heliyon.2025.e42720.


Prognosis and risk factor assessment of patients with advanced lung cancer with low socioeconomic status: model development and validation.

Cui J, An Z, Zhou X, Zhang X, Xu Y, Lu Y BMC Cancer. 2024; 24(1):1128.

PMID: 39256698 PMC: 11389553. DOI: 10.1186/s12885-024-12863-w.


Does needle gauge affect complication rates of computed tomography-guided lung biopsy?.

Jalaeian H, Richardson K, Kozlowski K, Patel A, Venkat S J Thorac Dis. 2024; 16(7):4310-4318.

PMID: 39144294 PMC: 11320254. DOI: 10.21037/jtd-24-240.


The Effect of MiR320a on Lung Cancer.

Hasani A Microrna. 2024; 13(3):167-174.

PMID: 38963099 DOI: 10.2174/0122115366296148240530072346.


Impact of Different Treatment Regimens and Timeframes in the Plasmatic Metabolic Profiling of Patients with Lung Adenocarcinoma.

Madama D, Carrageta D, Guerra-Carvalho B, Botelho M, Oliveira P, Cordeiro C Metabolites. 2023; 13(12).

PMID: 38132862 PMC: 10744969. DOI: 10.3390/metabo13121180.


References
1.
Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

2.
Pikor L, Ramnarine V, Lam S, Lam W . Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013; 82(2):179-89. DOI: 10.1016/j.lungcan.2013.07.025. View

3.
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

4.
Ramos P, Bentires-Alj M . Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2014; 34(28):3617-26. DOI: 10.1038/onc.2014.314. View

5.
Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View